Frank Witney Joins Ampersand as Operating Partner

Wellesley, MA. Ampersand Capital Partners, a healthcare-focused, middle market private equity firm, is pleased to announce the addition of Frank Witney, PhD, as an Operating Partner. Dr. Witney is actively working with Ampersand’s investment team to identify and evaluate new investment opportunities as well as assist in the existing portfolio.

Dr. Witney has a long and distinguished career in the laboratory products segment of the healthcare industry. Most recently, he served as President and CEO of publicly traded Affymetrix, a leading provider of genomics and cell biology products acquired by Thermo Fisher Scientific in 2016 for $1.3 billion. Previously, Dr. Witney was President and CEO of Dionex, a public company focused on analytical instruments for the separation sciences market. Dionex was acquired by Thermo Fisher Scientific in 2011 for $2.1 billion.

Dr. Witney has also held senior leadership positions at PerkinElmer, Packard Bioscience and Bio-Rad Laboratories. He holds a PhD in mole

< | >